Form 4 Filing for Acrivon Therapeutics, Inc. - Officer Stock Acquisition

This filing details a Form 4 submission by Adam D. Levy, Chief Financial Officer of Acrivon Therapeutics, Inc. (ACRV). On May 18, 2026, Mr. Levy acquired 46,167 shares of Common Stock through a transaction coded "A", indicating an acquisition. The transaction price was $0.00 per share, suggesting these shares were likely granted as restricted stock units (RSUs) or through a similar equity compensation plan. Following this transaction, Mr. Levy holds a total of 67,150 shares. The acquired shares represent RSUs that vest in installments starting November 18, 2026, subject to continued service with the company. This filing is classified as an officer transaction.